Stockscreener 앱 받기
16.01
0.20%
-0.0175
전일 마감가:
$16.03
열려 있는:
$16.03
하루 거래량:
224.64K
Relative Volume:
0.50
시가총액:
$5.71B
수익:
$5.21B
순이익/손실:
$-211.00M
주가수익비율:
-25.91
EPS:
-0.6179
순현금흐름:
$861.30K
1주 성능:
-0.01%
1개월 성능:
-2.98%
6개월 성능:
-3.62%
1년 성능:
+34.55%
1일 변동 폭
$15.86
$16.09
1주일 범위
$15.66
$16.32
52주 변동 폭
$10.99
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.00 | 5.72B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
430.06 | 148.77B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.51 | 39.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
38.73 | 33.19B | 29.14B | 1.07B | 1.52B | 1.1995 |
ALC
Alcon Inc
|
63.87 | 30.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
201.89 | 28.83B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Brent Saunders: Healthcare Innovation Leader, Global Pharmaceutical Executive, and Bausch + Lomb CEO - BBN Times
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
BLCO (BLCO) CFO has 63,938 shares withheld to cover RSU taxes - Stock Titan
Tax withholding trims Bausch & Lomb (NYSE: BLCO) EVP share count - Stock Titan
Bausch & Lomb (NYSE: BLCO) SVP has 8,673 shares withheld for RSU taxes - Stock Titan
Bausch & Lomb (BLCO) executive reports 11,970-share RSU tax withholding on Form 4 - Stock Titan
Bausch + Lomb launches Bi-Blade+ vitrectomy cutter in Europe - Investing.com
Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe – Company Announcement - Financial Times
June 1 webinar to detail lens material not seen in 25 years - Stock Titan
Bausch & Lomb Earnings: Vision Care Resilience and Pharmaceutical Rebound Lead Off 2026 - Morningstar Canada
H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
What Bausch + Lomb (BLCO)'s Upgraded 2026 Outlook and Narrowing Losses Mean For Shareholders - Yahoo Finance
Bausch & Lomb (BLCO) director receives 1,415 restricted share units - Stock Titan
Director at Bausch & Lomb (NYSE: BLCO) granted 1,611 RSUs - Stock Titan
Director John Paulson receives 1,375 RSUs in Bausch & Lomb (NYSE: BLCO) - Stock Titan
Bausch & Lomb (BLCO) director receives 1,375 restricted share units - Stock Titan
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $16 - Moomoo
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Align Tech (ALGN) and Bausch + Lomb Corporation (BLCO) - The Globe and Mail
Bausch & Lomb Corp Q1 2026 Financial Results and Risk Factors – Form 10-Q Highlights - Minichart
BofA Securities Maintains Bausch + Lomb Corp.(BLCO.US) With Sell Rating - 富途牛牛
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16 - 富途牛牛
Deutsche Bank Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $16 - 富途牛牛
Bausch + Lomb (NYSE:BLCO) Issues Earnings Results - MarketBeat
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting - BioSpace
A Quick Look at Today's Ratings for Bausch + Lomb Corp.(BLCO.US), With a Forecast Between $16 to $21 - 富途牛牛
Bausch + Lomb Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
From dry eye to glaucoma, 40+ Bausch + Lomb studies head to Denver - Stock Titan
BofA raises Bausch & Lomb stock price target on earnings beat - Investing.com UK
BofA raises Bausch & Lomb stock price target on earnings beat By Investing.com - Investing.com South Africa
Bausch Health Companies Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Bausch & Lomb Corp (BLCO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Bausch + Lomb Q1 Earnings Call Highlights - Yahoo Finance
Evercore ISI cuts Bausch & Lomb stock price target on growth outlook - Investing.com India
Evercore ISI cuts Bausch & Lomb stock price target on growth outlook By Investing.com - Investing.com South Africa
Bausch & Lomb 10-Q: Revenue $1,244M, Loss per Share $(0.20) - TradingView
Bausch + Lomb (BLCO) Q1 2026 revenue rises to $1.24B as loss narrows - Stock Titan
Earnings call transcript: Bausch + Lomb exceeds Q1 2026 earnings expectations By Investing.com - Investing.com Australia
Bausch + Lomb Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Bausch + Lomb exceeds Q1 2026 earnings expectations - Investing.com
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - Yahoo Finance
Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook - The AI Journal
Bausch + Lomb posts Q1 2026 revenue $1.244B, raises FY26 revenue and EBITDA outlook - TradingView
Stronger Q1 2026 drives Bausch + Lomb (NYSE: BLCO) to raise full-year outlook - Stock Titan
Dry-eye and lens sales lift Bausch + Lomb, prompting 2026 raise - Stock Titan
Bausch Health Companies Inc (BHC) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
bausch + lomb corporation Positive Earnings Pre-Announcements - RTTNews
Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Bausch & Lomb (NYSE: BLCO) executive reports tax-withheld 4,216-share RSU vesting - Stock Titan
RSU tax withholding adjusts Bausch & Lomb (NYSE: BLCO) holdings - Stock Titan
Icahn money manager sues his bosses and Bausch + Lomb over anti-white bias - MSN
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.04%
자본화:
|
볼륨(24시간):